These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37390678)

  • 1. Cognitive trajectories in relapsing-remitting multiple sclerosis: Evidence of multiple evolutionary trends.
    London F; De Haan A; Benyahia Z; Landenne G; Duprez T; van Pesch V; El Sankari S
    Mult Scler Relat Disord; 2023 Sep; 77():104848. PubMed ID: 37390678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcome measurements in a selective cohort of relapsing-remitting multiple sclerosis patients: relationships with physical disability, cognitive impairment, and MRI-derived metrics.
    London F; El Sankari S; De Haan A; Benyahia Z; Landenne G; Duprez T; van Pesch V
    Acta Neurol Belg; 2023 Jun; 123(3):1049-1059. PubMed ID: 36877357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.
    Marstrand L; Østerberg O; Walsted T; Skov AC; Schreiber KI; Sellebjerg F
    Mult Scler Relat Disord; 2020 Jan; 37():101458. PubMed ID: 31683230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study.
    Kania K; Pawlak MA; Forycka M; Wiłkość-Dębczyńska M; Michalak S; Łukaszewska A; Wyciszkiewicz A; Wypych A; Serafin Z; Marcinkowska J; Kozubski W; Kalinowska-Łyszczarz A
    Neurol Neurochir Pol; 2024; 58(2):176-184. PubMed ID: 38324117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between cognitive and clinical disability across MS subtypes: The role of the underlying brain damage.
    Gois LCP; Pimentel-Silva LR; Damasceno BP; Damasceno A
    Mult Scler Relat Disord; 2021 Feb; 48():102701. PubMed ID: 33477004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.
    Dong X; Xu G; Wang J; Yin N; Meng N
    Mult Scler Relat Disord; 2022 Sep; 65():103838. PubMed ID: 35749960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS.
    Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
    Mult Scler Relat Disord; 2020 Nov; 46():102577. PubMed ID: 33296975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS).
    Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
    Mult Scler Relat Disord; 2019 Nov; 36():101408. PubMed ID: 31610403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Damasceno A; Pimentel-Silva LR; Damasceno BP; Cendes F
    Mult Scler; 2020 Nov; 26(13):1740-1751. PubMed ID: 31603042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS).
    O'Connell K; Langdon D; Tubridy N; Hutchinson M; McGuigan C
    Mult Scler Relat Disord; 2015 Nov; 4(6):521-5. PubMed ID: 26590658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
    Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
    Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
    Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalcortical thickness in relapsing-remitting multiple sclerosis, correlations with cognition impairment, and effect of modified Bushenyisui decoction on cognitive function of multiple sclerosis.
    Zhao X; Yang T; Cheng F; Yang S; Zhu W; Li S; Fan Y
    J Tradit Chin Med; 2021 Apr; 41(2):316-325. PubMed ID: 33825413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
    Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
    Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enlarged choroid plexus related to iron rim lesions and deep gray matter atrophy in relapsing-remitting multiple sclerosis.
    Wang X; Zhu Q; Yan Z; Shi Z; Xu Y; Liu Y; Li Y
    Mult Scler Relat Disord; 2023 Jul; 75():104740. PubMed ID: 37146422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and structural connectivity substrates of cognitive performance in relapsing remitting multiple sclerosis with mild disability.
    Has Silemek AC; Fischer L; Pöttgen J; Penner IK; Engel AK; Heesen C; Gold SM; Stellmann JP
    Neuroimage Clin; 2020; 25():102177. PubMed ID: 32014828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.